pegunigalsidase alfa

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Fabry Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (1)
EU
  • Elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).
Product first approved 2023EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Fabry Disease
NCT03180840 · Protalix
2017-07-10 – 2020-08-01 · Fabry Disease
What this study did
NCT03018730 · Protalix
2017-05-17 – 2020-01-09 · Fabry Disease
What this study did
NCT02921620 · Protalix
2017-07 – 2018-07 · Fabry Disease
What this study did
Phase 2/3 (2)
Fabry Disease
NCT06328608 · Chiesi Farmaceutici S.p.A.
2025-07-29 – 2031-04 · Fabry Disease
What this study did
NCT05710692 · Chiesi Farmaceutici S.p.A.
2023-08-01 – 2029-08 · Fabry Disease
What this study did
Phase 1/2 (2)
Fabry Disease
NCT01981720 · Protalix
2014-01-16 – 2021-11-09 · Fabry Disease
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Fabry Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pegunigalsidase Alfa: this drugApprovedProtein / enzyme therapeuticAlpha-galactosidase A (GLA / α-Gal A)Weak signal
NCT02795676: Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months): PRX-102 (Pegunigalsidase Alfa) -2.514 mL/min/1.73 m^2/year (95% CI -3.788 to -1.24) | Agalsidase Beta -2.155 mL/min/1.73 m^2/year (95% CI -3.805 to -0.505)
Agalsidase Beta (Fabrazyme)ApprovedProtein / enzyme therapeuticAlpha-galactosidase A (GLA / α-Gal A)Weak signal
NCT00701415: Participants with zero skin GL-3 score: 75% vs 80% at week 52, 56.3% vs 80% at week 156, and 68.8% vs 66.7% at week 260 (0.5 mg/kg every 2 weeks vs 1.0 mg/kg every 4 weeks).
NCT00196716: Open-label low-dose-maintenance study, 21 adult Fabry males (matches registry enrollment_count 21): kidney interstitial capillary endothelial GL-3 clearance (primary endpoint) achieved in 100% of patients during the 1.0mg/kg/2wk standard-dose phase and maintained in 90% after switching to the 0.3mg/kg/2wk low-dose maintenance phase.
Migalastat (Galafold)ApprovedSmall moleculeAlpha-galactosidase A (GLA / α-Gal A)Partial signal
NCT00925301: Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Migalastat — Responder: 13 Participants; Non-Responder: 19 Participants | Placebo — Responder: 9 Participants; Non-Responder: 23 Participants missed
Isaralgagene CivaparvovecPhase 1/2Gene therapy / editingAlpha-galactosidase A (GLA / α-Gal A)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow pegunigalsidase alfa to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
Phase 2/3Fabry DiseaseRecruiting
Est. primary completion 2027-10 · NCT05710692 · CT.gov ↗
What to watch
2028 (1)
October 2028 (1)
Phase 2/3Fabry DiseaseRecruiting
Est. primary completion 2028-10 · NCT06328608 · CT.gov ↗
What to watch

See the full readout calendar ↗